Inverse relationship between tumor proliferation markers and connexin expression in a malignant cardiac tumor originating from mesenchymal stem cell engineered tissue in a rat in vivo model

Frontiers in Pharmacology

Volumn 4 APR, Issue , 2013, Pages

  Spath, Cathleen ^a   Schlegel, Franziska ^a   Leontyev, Sergey ^b   Mohr, Friedrich Wilhelm ^b   Dhein, Stefan ^b  

^a Translational Centre for Regenerative Medicine   (Germany)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

Author keywords

Connexins; Cx40; Cx43; Cx45; Gap junctions; Proliferation; Sarcoma; Tumour

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CONNEXIN 40; CONNEXIN 43; CONNEXIN 45; GAP JUNCTION PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; FLOW CYTOMETRY; GAP JUNCTION; HEART SARCOMA; HEART TRANSPLANTATION; HEART TUMOR; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TISSUE ENGINEERING; TUMOR GROWTH; TUMOR INVASION;

EID: 84881491984     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00042     Document Type: Article

References (78)

1. Ai, Z., Fischer, A., Spray, D. C., Brown, A. M., and Fishman, G. I. (2000). Wnt-1 regulation of connexin43 in cardiac myocytes. J. Clin. Invest. 105, 161-171.
2. Angervall, L., Hagmar, B., Kindblom, L. G., and Merck, C. (1981). Malignant giant cell tumor of soft tissues: a clinicopathologic, cytologic, ultrastructural, angiographic, and microangiographic study. Cancer 47, 736-747.
3. Bang, O. Y., Lee, J. S., Lee, P. H., and Lee, G. (2005). Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 57, 874-882.
4. Barcellos-Hoff, M. H., and Brooks, A. L. (2001). Extracellular signaling through the microenvironment: a hypothesis relating carcinogenesis, bystander effects, and genomic instability. Radiat. Res. 156, 618-627.
5. Chin, S. P., Poey, A. C., Wong, C. Y., Chang, S. K., Teh, W., Mohr, T. J., et al. (2010). Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy. Cytotherapy 12, 31-37.
6. Cronier, L., Crespin, S., Strale, P. O., Defamie, N., and Mesnil, M. (2009). Gap junctions and cancer: new functions for an old story. Antioxid. Redox Signal. 11, 323-338.
7. Dei Tos, A. P. (2006). Classification of pleomorphic sarcomas: where are we now? Histopathology 48, 51-62.
8. Deyrup, A. T., and Weiss, S. W. (2006). Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology 48, 42-50.
9. Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837-3844.
10. Doble, B. W., and Woodgett, J. R. (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186.
11. Dobson, K. R., Reading, L., Haberey, M., Marine, X., and Scutt, A. (1999). Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif. Tissue Int. 65, 411-413.
12. Elzarrad, M. K., Haroon, A., Willecke, K., Dobrowolski, R., Gillespie, Elzarrad, M. K., Haroon, A., Willecke, K., Dobrowolski, R., Gillespie, M. N., and Al-Mehdi, A. B. (2008). Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium. BMC Med. 6:20. doi:10.1186/1741-7015-6-20
13. Evans, W. H., and Martin, P. (2002). Gap junctions: structure and function. Mol. Membr. Biol. 19, 121-136.
14. Ezumi, K., Yamamoto, H., Murata, K., Higashiyama, M., Damdinsuren, B., Nakamura, Y., et al. (2008). Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin. Cancer Res. 14, 677-684.
15. Fletcher, C. D. (1992). Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am. J. Surg. Pathol. 16, 213-228.
16. Fu, C. T., Bechberger, J. F., Ozog, M. A., Perbal, B., and Naus, C. C. (2004). CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J. Biol. Chem. 279, 36943-36950.
17. Gellhaus, A., Dong, X., Propson, S., Maass, K., Klein-Hitpass, L., Kibschull, M., et al. (2004). Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells. J. Biol. Chem. 279, 36931-36942.
18. Giepmans, B. N., and Moolenaar, W. H. (1998). The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein. Curr. Biol. 8, 931-934.
19. Guccion, J. G., and Enzinger, F. M. (1972). Malignant giant cell tumor of soft parts. An analysis of 32 cases. Cancer 29, 1518-1529.
20. Guillou, L., Coindre, J. M., Bonichon, F., Nguyen, B. B., Terrier, P., Collin, F., et al. (1997). Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J. Clin. Oncol. 15, 350-362.
21. Gunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., and Gregory, C. A. (2006). A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24, 986-991.
22. Hagen, A., Dietze, A., and Dhein, S. (2009). Human cardiac gap junction coupling: effects of antiarrhythmic peptide AAP10. Cardiovasc. Res. 83, 405-415.
23. Holnthoner, W., Pillinger, M., Groger, M., Wolff, K., Ashton, A. W., Albanese, C., et al. (2002). Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells. J. Biol. Chem. 277, 45847-45853.
24. Hong, D., Chen, H. X., Xue, Y., Li, D. M., Wan, X. C., Ge, R., et al. (2009). Osteoblastogenic effects of dexamethasone through upregulation of TAZ expression in rat mesenchymal stem cells. J. Steroid Biochem. Mol. Biol. 116, 86-92.
25. Horwitz, E. M., Prockop, D. J., Fitzpatrick, L. A., Koo, W. W., Gordon, P. L., Neel, M., et al. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5, 309-313.
26. Iacobas, D. A., Iacobas, S., Li, W. E., Zoidl, G., Dermietzel, R., and Spray, D. C. (2005a). Genes controlling multiple functional pathways are transcriptionally regulated in connexin43 null mouse heart. Physiol. Genomics 20, 211-223.
27. Iacobas, D. A., Iacobas, S., and Spray, D. C. (2005b). "Use of cDNA aarays to explore gene expression in genetically manipulated mice and cell lines," in Practical Methods in Cardiovascular Research, eds S. Dhein, F. W. Mohr, and M. Delmar (Berlin: Springer), 907-915.
28. Ito, A., Katoh, F., Kataoka, T. R., Okada, M., Tsubota, N., Asada, H., et al. (2000). A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J. Clin. Invest. 105, 1189-1197.
29. Kalimi, G. H., Hampton, L. L., Trosko, J. E., Thorgeirsson, S. S., and Huggett, A. C. (1992). Homologous and heterologous gap-junctional intercellular communication in v-raf-, v-myc-, and v-raf/v-myc-transduced rat liver epithelial cell lines. Mol. Carcinog. 5, 301-310.
30. Kanczuga-Koda, L., Koda, M., Sulkowski, S., Wincewicz, A., Zalewski, B., and Sulkowska, M. (2010). Gradual loss of functional gap junction within progression of colorectal cancer - a shift from membranous CX32 and CX43 expression to cytoplasmic pattern during colorectal carcinogenesis. In vivo 24, 101-107.
31. Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563.
32. Karussis, D., Kassis, I., Kurkalli, B. G., and Slavin, S. (2008). Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J. Neurol. Sci. 265, 131-135.
33. Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., et al. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203, 1235-1247.
34. King, T. J., Fukushima, L. H., Donlon, T. A., Hieber, A. D., Shimabukuro, K. A., and Bertram, J. S. (2000a). Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression. Carcinogenesis 21, 311-315.
35. King, T. J., Fukushima, L. H., Hieber, A. D., Shimabukuro, K. A., Sakr, W. A., and Bertram, J. S. (2000b). Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 21, 1097-1109.
36. Kurtova, A. V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M. P., et al. (2009). Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114, 4441-4450.
37. Laird, D. W., Fistouris, P., Batist, G., Alpert, L., Huynh, H. T., Carystinos, G. D., et al. (1999). Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res. 59, 4104-4110.
38. Lampe, P. D. (1994). Analyzing phorbol ester effects on gap junctional communication: a dramatic inhibition of assembly. J. Cell Biol. 127, 1895-1905.
39. Leontyev, S., Schlegel, F., Spath, C., Schmiedel, R., Nichtitz, M., Boldt, A., et al. (2013). Transplantation of engineered heart tissue (EHT) as biological cardiac assist device for treatment of dilated cardiomyopathy. Eur. J. Heart Fail. 15, 23-35.
40. Lin, J. H., Takano, T., Cotrina, M. L., Arcuino, G., Kang, J., Liu, S., et al. (2002). Connexin43 enhances the adhesivity and mediates the invasion of malignant glioma cells. J. Neurosci. 22, 4302-4311.
41. Loewenstein, W. R. (1980). Junctional cell-to-cell communication and growth control. Ann. N. Y. Acad. Sci. 339, 39-45.
42. Loewenstein, W. R., and Kanno, Y. (1966). Intercellular communication and the control of tissue growth: lack of communication between cancer cells. Nature 209, 1248-1249.
43. Maestroni, G. J., Hertens, E., and Galli, P. (1999). Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell. Mol. Life Sci. 55, 663-667.
44. Mesnil, M., Asamoto, M., Piccoli, C., and Yamasaki, H. (1994). Possible molecular mechanism of loss of homologous and heterologous gap junctional intercellular communication in rat liver epithelial cell lines. Cell Adhes. Commun. 2, 377-384.
45. Mesnil, M., Crespin, S., Avanzo, J. L., and Zaidan-Dagli, M. L. (2005). Defective gap junctional intercellular communication in the carcinogenic process. Biochim. Biophys. Acta 1719, 125-145.
46. Miura, M., Miura, Y., Padilla-Nash, H. M., Molinolo, A. A., Fu, B., Patel, V., et al. (2006). Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24, 1095-1103.
47. Momiyama, M., Omori, Y., Ishizaki, Y., Nishikawa, Y., Tokairin, T., Ogawa, J., et al. (2003). Connexin26-mediated gap junctional communication reverses the malignant phenotype of MCF-7 breast cancer cells. Cancer Sci. 94, 501-507.
48. Nagaya, N., Kangawa, K., Itoh, T., Iwase, T., Murakami, S., Miyahara, Y., et al. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112, 1128-1135.
49. Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., et al. (2004). Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11, 1155-1164.
50. Naoi, Y., Miyoshi, Y., Taguchi, T., Kim, S. J., Arai, T., Tamaki, Y., et al. (2007). Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. Breast Cancer Res. Treat. 106, 11-17.
51. Naus, C. C., and Laird, D. W. (2010). Implications and challenges of connexin connections to cancer. Nat. Rev. Cancer 10, 435-441.
52. Ohlsson, L. B., Varas, L., Kjellman, C., Edvardsen, K., and Lindvall, M. (2003). Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp. Mol. Pathol. 75, 248-255.
53. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147.
54. Romanov, Y. A., Svintsitskaya, V. A., and Smirnov, V. N. (2003). Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 21, 105-110.
55. Rubio, D., Garcia-Castro, J., Martín, M. C., de la Fuente, R., Cigudosa, J. C., Lloyd, A. C., et al. (2005). Spontaneous human adult stem cell transformation. Cancer Res. 65, 3035-3039.
56. Saito-Katsuragi, M., Asada, H., Niizeki, H., Katoh, F., Masuzawa, M., Tsutsumi, M., et al. (2007). Role for connexin 26 in metastasis of human malignant melanoma: communication between melanoma and endothelial cells via connexin 26. Cancer 110, 1162-1172.
57. Salameh, A., and Dhein, S. (2005). Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim. Biophys. Acta 1719, 36-58.
58. Sato, H., Hagiwara, H., Senba, H., Fukumoto, K., Nagashima, Y., Yamasaki, H., et al. (2008). The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma. Mol. Carcinog. 47, 403-409.
59. Söhl, G., and Willecke, K. (2004). Gap junctions and the connexin protein family. Cardiovasc. Res. 62, 228-232.
60. Sourisseau, T., Georgiadis, A., Tsapara, A., Ali, R. R., Pestell, R., Matter, K., et al. (2006). Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol. Cell. Biol. 26, 2387-2398.
61. Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 4:e4992. doi:10.1371/journal.pone.0004992
62. Strawn, W. B., Richmond, R. S., Ann Tallant, E., Gallagher, P. E., and Ferrario, C. M. (2004). Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br. J. Haematol. 126, 120-126.
63. Tang, J., Wang, J., Yang, J., Kong, X., Zheng, F., Guo, L., et al. (2009). Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur. J. Cardiothorac. Surg. 36, 644-650.
64. Tian, K., Yang, S., Ren, Q., Han, Z., Lu, S., Ma, F., et al. (2010). p38 MAPK contributes to the growth inhibition of leukemic tumor cells mediated by human umbilical cord mesenchymal stem cells. Cell. Physiol. Biochem. 26, 799-808.
65. Tolar, J., Nauta, A. J., Osborn, M. J., Panoskaltsis Mortari, A., McElmurry, R. T., Bell, S., et al. (2007). Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25, 371-379.
66. Trosko, J. E., Chang, C. C., Madhukar, B. V., and Dupont, E. (1993). "Oncogenesis, tumor suppressor genes, and intercellular communication in the 'oncogeny as partially blocked ontogeny' hypothesis," in New Frontiers in Cancer Causation, ed. O. H. Iversen (Washington: Taylor & Francis), 181-197.
67. Trosko, J. E., Chang, C. C., Madhukar, B. V., and Klaunig, J. E. (1990). Chemical, oncogene and growth factor inhibition gap junctional intercellular communication: an integrative hypothesis of carcinogenesis. Pathobiology 58, 265-278.
68. Trosko, J. E., Chang, C. C., Upham, B. L., and Tai, M. H. (2004). Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication. Ann. N. Y. Acad. Sci. 1028, 192-201.
69. Valiunas, V., Doronin, S., Valiuniene, L., Potapova, I., Zuckerman, J., Walcott, B., et al. (2004). Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J. Physiol. (Lond.) 555(Pt 3), 617-626.
70. Wan, X. C., Liu, C. P., Li, M., Hong, D., Li, D. M., Chen, H. X., et al. (2008). Staphylococcal enterotoxin C injection in combination with ascorbic acid promotes the differentiation of bone marrow-derived mesenchymal stem cells into osteoblasts in vitro. Biochem. Biophys. Res. Commun. 373, 488-492.
71. Wong, R. S. (2011). Mesenchymal stem cells: angels or demons? J. Biomed. Biotechnol. 2011, 459510.
72. Yamasaki, H., Mesnil, M., Omori, Y., Mironov, N., and Krutovskikh, V. (1995). Intercellular communication and carcinogenesis. Mutat. Res. 333, 181-188.
73. Yano, T., Fujimoto, E., Hagiwara, H., Sato, H., Yamasaki, H., Negishi, E., et al. (2006). Connexin 32 as an anti-invasive and anti-metastatic gene in renal cell carcinoma. Biol. Pharm. Bull. 29, 1991-1994.
74. Zhang, Z. Q., Zhang, W., Wang, N. Q., Bani-Yaghoub, M., Lin, Z. X., and Naus, C. C. (1998). Suppression of tumorigenicity of human lung carcinoma cells after transfection with connexin43. Carcinogenesis 19, 1889-1894.
75. Zhou, Y. F., Bosch-Marce, M., Okuyama, H., Krishnamachary, B., Kimura, H., Zhang, L., et al. (2006). Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res. 66, 10849-10854.
76. Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., et al. (2006). Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp. Mol. Pathol. 80, 267-274.
77. Zimmermann, W. H., Melnychenko, I., Wasmeier, G., Didie, M., Naito, H., Nixdorff, U., et al. (2006). Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 12, 452-458.
78. Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., et al. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7, 211-228.